M1/M2 Macrophages in Diabetic Nephropathy: Nrf2/HO-1 as Therapeutic Targets

E-ISSN： 1873-4286|24|20|2241-2249

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.24, Iss.20, 2018-06, pp. : 2241-2249

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Muscarinic M1 receptor agonists and M2 receptor antagonists as therapeutic targets in Alzheimer’s disease

By Sheardown Malcolm J

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 6, 2002-06 ,pp. : 863-870

Informa Healthcare

Access to resources Recommend Favorite

Novel Therapeutic Targets for Diabetic Nephropathy

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 7, Iss. 2, 2007-06 ,pp. : 83-92

Bentham Science Publishers

Access to resources Recommend Favorite

Bone morphogenetic protein 7 polarizes THP-1 cells into M2 macrophages

By Rocher Crystal Singla Reetu Singal Pawan K. Parthasarathy Sampath Singla Dinender K.

Canadian Journal of Physiology and Pharmacology, Vol. 90, Iss. 7, 2012-07 ,pp. : 947-951

NRC Research Press

Access to resources Recommend Favorite

Neohesperidin attenuates cerebral ischemia–reperfusion injury via inhibiting the apoptotic pathway and activating the Akt/Nrf2/HO-1 pathway

By Wang Ji-Jun Cui Ping

Journal of Asian Natural Products Research, Vol. 15, Iss. 9, 2013-09 ,pp. : 1023-1037

Taylor & Francis Ltd

Access to resources Recommend Favorite

Adenosine Receptors: New Therapeutic Targets for Inflammation in Diabetic Nephropathy

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 12, Iss. 3, 2013-06 ,pp. : 153-161

Bentham Science Publishers

Access to resources Recommend Favorite